| Literature DB >> 34864809 |
Yongtao Wang1, Lejun Lin1, Wei Quan2, Jinyu Li1, Weilong Li1.
Abstract
OBJECTIVE: Recently, a new Bayesian penalty likelihood (BPL) reconstruction algorithm has been applied in PET, which is expected to provide better image resolution than the widely used ordered subset expectation maximization (OSEM). The purpose of this study is to compare the differences between these two algorithms in terms of image quality and effects on clinical diagnostics and quantification of lymphoma.Entities:
Mesh:
Year: 2022 PMID: 34864809 PMCID: PMC8826614 DOI: 10.1097/MNM.0000000000001516
Source DB: PubMed Journal: Nucl Med Commun ISSN: 0143-3636 Impact factor: 1.690
Basic information of the examinee
| Clinical info | Clinical data |
|---|---|
| Gender female/male (%) | 28 (40%)/42 (60%) |
| Age (years-old) | 51.67 ± 16.09 (19–83) |
| BMI (kg/m3) | 24.58 ± 4.03 (14.88–33.91) |
| The dose of 18F-FDG (MBq/kg) | 3.67 ± 0.01 (3.65–3.69) |
| Glucose (mmol/l) | 5.86 ± 1.03 (4.7–11) |
| Diagnostic (Pathology) | |
| Hodgkin (%) | 8 (11.43%) |
| Non-Hodgkin (%) | 62 (88.57%) |
| Diffuse large B cells (%) | 31 (44.29%) |
| Follicular lymphoma (%) | 18 (25.71%) |
| others(%) | 13 (18.57%) |
Fig. 1Visual scores of clinical image quality and diagnostic certainty using Bayesian penalty likelihood (BPL) and non-BPL algorithms.
Fig. 2The clinical case showed a 57-year-old female with non-Hodgkin’s lymphoma (B-cell type) in August 2020. Before treatment, systemic PET-CT examination was performed to evaluate the image reconstructed by the following: (a) using BPL, the right maxillofacial lymph node focus SUVmax = 7.28, clinician scored 4 points for image quality and diagnostic accuracy. (b) using OSEM + PSF + TOF, the right maxillofacial lymph node lesion SUVmax = 5.43. Clinicians scored 2 points for image quality and 2 points for diagnostic accuracy. BPL, Bayesian penalty likelihood; CT, computed tomography; OSEM, ordered subset expectation maximization; PSF, point spread function; SUV, standardized uptake value; TOF, time-of-flight.
Statistical results of metabolic parameters between two groups with different reconstruction parameters
| Quantitative parameter | BPL | Non-BPL | |
|---|---|---|---|
| Lesion SUVmax | 15.25 ± 10.17 | 12.97 ± 7.87 | 0.000 |
| Lesion MTV | 4.18 ± 7.10 | 4.29 ± 6.37 | 0.273 |
| Lesion TLG | 43.00 ± 104.58 | 39.36 ± 93.41 | 0.000 |
| Background liver SUVmean | 2.52 ± 0.27 | 2.51 ± 0.30 | 0.558 |
| SBR | 6.02 ± 4.13 | 5.14 ± 3.54 | 0.000 |
BPL, Bayesian penalty likelihood; MTV, metabolic tumor volume; SBR, signal-to-background ratio; SUV, standardized uptake value; TLG, total-lesion-glycolysis.
Correlation analysis between the change of metabolic parameters and the diameter of lesions
| Pearson | Diameter (1.56 ± 1.22) | |
|---|---|---|
| ΔSUVmax% (16.92% ± 29.12%) | −0.187 | 0.003 |
| ΔSBR% (19.30% ± 30.92%) | −0.177 | 0.005 |
| ΔMTV% (30.31% ± 85.55%) | 0.138 | 0.031 |
| ΔTLG% (6.6020% ± 68.80%) | 0.13 | 0.04 |
MTV, metabolic tumor volume; SBR, signal-to-background ratio; SUV, standardized uptake value; TLG, total-lesion-glycolysis.
Results of metabolic parameters among different pathological groups
| 1 = Hodgkin | 2 = Diffuse large B | 3 = Follicular | 4 = Others | |
|---|---|---|---|---|
| Nodules (number) | 59 | 102 | 69 | 16 |
| Diameter (cm) | 1.58 ± 1.20 | 1.72 ± 1.59 | 1.46 ± 0.51 | 0.91 ± 0.35 |
| SUVmax-BPL | 14.10 ± 7.07 | 17.92 ± 13.04 | 13.39 ± 7.29 | 10.71 ± 4.99 |
| SUVmean-BPL | 8.75 ± 4.62 | 11.77 ± 9.47 | 8.59 ± 5.02 | 6.80 ± 3.58 |
| MTV-BPL | 6.53 ± 12.79 | 3.72 ± 4.13 | 3.37 ± 3.06 | 1.73 ± 1.61 |
| Liver SUVmean-BPL | 2.46 ± 0.36 | 2.56 ± 0.38 | 2.53 ± 0.54 | 2.47 ± 0.42 |
| TLG-BPL | 75.61 ± 192.20 | 41.40 ± 61.94 | 25.16 ± 25.87 | 9.81 ± 8.70 |
| SBR-BPL | 5.74 ± 3.18 | 7.18 ± 5.19 | 5.69 ± 3.71 | 4.21 ± 1.44 |
| SUVmax-non BPL | 12.07 ± 6.32 | 14.88 ± 9.57 | 11.90 ± 6.43 | 8.70 ± 2.26 |
| SUVmean-non BPL | 7.11 ± 3.58 | 9.03 ± 5.96 | 7.21 ± 4.06 | 5.21 ± 1.42 |
| MTV-non BPL | 6.67 ± 11.38 | 3.82 ± 3.63 | 3.57 ± 3.05 | 1.67 ± 1.24 |
| Liver SUVmean-non BPL | 2.50 ± 0.38 | 2.54 ± 0.46 | 2.55 ± 0.55 | 2.26 ± 0.30 |
| TLG-non BPL | 68.06 ± 172.09 | 37.92 ± 54.39 | 23.99 ± 24.35 | 8.97 ± 8.30 |
| SBR-non BPL | 4.97 ± 2.68 | 6.05 ± 4.15 | 4.99 ± 3.28 | 3.83 ± 0.80 |
| ΔSUVmax% | 18.68% ± 21.93% | 18.56% ± 36.71% | 12.83% ± 18.59% | 20.20% ± 34.35% |
| ΔSBR% | 19.03% ± 27.96% | 20.15% ± 38.84% | 14.41% ± 23.98% | 10.15% ± 28.48% |
| ΔMTV% | −37.83% ± 65.57% | −78.66% ± 452.34% | −18.26% ± 33.49% | −22.28% ± 48.53% |
| ΔTLG% | −7.59% ± 32.96% | −13.63% ± 101.84% | 2.18% ± 19.64% | 4.04% ± 20.02% |
BPL, Bayesian penalty likelihood; MTV, metabolic tumor volume; SBR, signal-to-background ratio; SUV, standardized uptake value; TLG, total-lesion-glycolysis.
Fig. 3Diagram of metabolic parameters among different pathological groups.
Comparison of metabolic parameters of different lesion sizes
| Diameter | Parameter | Mean | SD | T | |
|---|---|---|---|---|---|
| D < 1 cm | SUVmax | 3.31 | 5.97 | 4.33 | 0.000 |
| SUVmean | 1.72 | 1.82 | 9.00 | 0.000 | |
| MTV | −0.39 | 0.73 | −4.15 | 0.000 | |
| Liver SUVmean | 0.01 | 0.21 | 0.31 | 0.756 | |
| TLG | −0.98 | 3.68 | −2.09 | 0.041 | |
| SBR | 1.23 | 2.42 | 3.97 | 0.000 | |
| 1 cm < D <2 cm | SUVmax | 2.27 | 4.50 | 6.05 | 0.000 |
| SUVmean | 1.92 | 2.43 | 14.23 | 0.000 | |
| MTV | −0.30 | 1.09 | −3.31 | 0.001 | |
| Liver SUVmean | 0.01 | 0.17 | 0.99 | 0.326 | |
| TLG | 0.63 | 5.89 | 1.28 | 0.203 | |
| SBR | 0.87 | 2.00 | 5.24 | 00.000 | |
| D > 2 cm | SUVmax | 0.92 | 3.05 | 1.96 | 0.057 |
| SUVmean | 0.64 | 4.95 | 5.54 | 0.052 | |
| MTV | 0.85 | 2.95 | 1.87 | 0.069 | |
| Liver SUVmean | −0.01 | 0.17 | −0.57 | 0.572 | |
| TLG | 20.59 | 32.56 | 4.10 | 0.000 | |
| SBR | 0.37 | 2.25 | 1.05 | 0.298 |
MTV, metabolic tumor volume; SBR, signal-to-background ratio; SUV, standardized uptake value; TLG, total-lesion-glycolysis.